Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for $2.65 billion, comprising a $1.55bn upfront payment and up to $1.1bn in milestones. The deal includes the asset sevasemten, currently in development for Becker and Duchenne muscular dystrophies. Approved by both boards, the transaction awaits regulatory clearance and is expected to close in Q3 2026, aligning with Servier's rare neurology strategy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Pharmaceutical Technology The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments